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SUMMARY
Macrophage migration inhibitory factor (MIF) may play an important
role in the pathogenesis of acute graft-versus-host disease (aGVHD)
after allogeneic hematopoietic stem cell transplantation (allo-HSCT), as
MIF plays an important role to regulate the production of tumor
necrosis factor-a (TNF-a), one of the inflammatory cytokines which
induces and exacerbates aGVHD. We examined the association
between serum MIF levels and aGVHD vs. chronic GVHD (cGVHD)
in allo-SCT patients in this study. We found a significant increase in the
peak serum MIF (14.46 ng ± 1.47 ng/ml) at onset in patients that
developed aGVHD (n = 23, P = 0.009). We also found that mean
serum MIF levels in patients who developed extensive type cGVHD
within 6 months (12.58 ± 2.18 ng/ml, n = 13) were significantly
higher than MIF levels before allo-HSCT (7.86 ± 1.17 ng/ml, n = 19,
P = 0.04). Therefore, we speculated that serum MIF levels increase
during the active phase of both aGVHD and cGVHD.
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INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(allo-HSCT) is an important curative therapy for
hematological malignancies. However, acute graft-ver-
sus-host disease (aGVHD) has been a major complica-
tion after allo-HSCT (Ferrara & Deeg, 1991). The
pathophysiology of aGVHD is a complex process
which can be conceptualized as a three-step process:
conditioning effect phase, T-cell activation phase, and
cellular and inflammatory effector phase (Ferrara,
Cooke & Teshima, 2003; Reddy & Ferrara, 2003).
Moreover, the activation and expansion of donor T
cells leads to the secretion of proinflammatory cyto-
kines and the recruitment of additional inflammatory
effector cells to several target organs (gut, liver, and
skin). This induces further damage to the affected tis-
sues (Shlomchik et al., 1999; Hill & Ferrara, 2000). In
contrast, chronic GVHD (cGVHD) is a complex multi-
organ disorder with features of autoimmunity and
immunodeficiency (Graze & Gale, 1979; Shulman
et al., 1980) and it remains to be the major cause of
late death and morbidity after allo-HSCT (Socie et al.,
1999; Baker et al., 2004).
Macrophage migration inhibitory factor (MIF) was
originally discovered as a lymphokine reported to pre-
vent the random migration of macrophages, recruiting
them instead to sites of inflammation (Bloom & Ben-
nett, 1966; David, 1966). Recent studies have revealed
that MIF is ubiquitously expressed in various types of
cells, especially T cells and macrophages, and has been
re-evaluated as a pluripotent cytokine involved in
broad-spectrum control of the immune system
(Bucala, 1996; Nishihira, 2000). It has also been
shown to be a proinflammatory cytokine and pitui-
tary-derived hormone which potentiates endotoxemia
(Bernhagen et al., 1993). Subsequent work showed
that T cells and macrophages secrete MIF in response
to glucocorticoids as well as upon activation by vari-
ous pro-inflammatory stimuli (Calandra et al., 1994).
Moreover, it has been suggested that tumor necrosis
factor-a (TNF-a) and interferon gamma (IFN-c) up-
regulate MIF production in macrophages and that,
conversely, MIF induces TNF-a production, forming a
proinflammatory loop within the cytokine network
(Calandra et al., 1994). Furthermore, anti-MIF anti-
bodies inhibit T-cell proliferation and IL-2 production
in vitro and suppress antigen-driven T-cell activation
and antibody production in vivo (Bacher et al., 1996).
MIF therefore plays an important role in the patho-
genesis of inflammatory diseases. The serum level and
the local expression level of MIF are significantly
increased in inflammatory diseases such as rheuma-
toid arthritis (Onodera et al., 1999), acute pulmonary
diseases (Donnelly et al., 1997), glomerulonephritis
(Lan et al., 2000), focal glomerular sclerosis
(Matsumoto et al., 2005), systemic sclerosis (Selvi
et al., 2003), chronic colitis, and experimental colitis
(de Jong et al., 2001; Ohkawara et al., 2002). Recent
studies have shown local MIF expression to be up-reg-
ulated in the allo-immune reaction during renal trans-
plantation and bone marrow (BM) transplantation. It
also co-localizes with macrophage and T-cell infiltra-
tion (Lan et al., 1998; Brown et al., 1999; Lo et al.,
2002; Jose et al., 2003; Toubai et al., 2006). We found
an association between local MIF expression and aG-
VHD in murine models using MIF knock out mice
(Toubai et al., 2006). The aGVHD scores and patholog-
ical findings in this study showed that MIF-deficient
lymphocytes do not induce severe aGVHD (Toubai
et al., 2006). These observations suggest that MIF may
also play an important role in the pathogenesis of aG-
VHD after allo-HSCT. We therefore set out to deter-
mine whether or not serum MIF has an influence on
aGVHD and cGVHD outcome after allo-HSCT.
PATIENTS AND METHODS
Patients’ characteristics
Archived specimen samples from 45 consecutive
patients undergoing HSCT from January 2000 to June
2005 at Hokkaido University Hospital, Sapporo, were
studied. All the patients were informed of, and con-
sented to, sample collection and usage. Their clinical
characteristics are shown in Table 1. The 45 patients
included 24 males and 21 females with the median
age of 37 (range, 16–65) years. Primary diseases were
13 chronic myelogenous leukemia, nine acute mye-
logenous leukemia (AML), nine myelodysplastic syn-
drome (MDS), six acute lymphoblastic leukemia, four
non-Hodgkin lymphoma (NHL), two adult T-cell leu-
kemia (ATL), one multiple myeloma and one aplastic
anemia. We defined the risk as follows: 1) standard
risk: AML 1st and 2nd CML, MDS refractory anemia
(RA), NHL 1st CR, 2) high risk: AML 3rd CR, non-CR,
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MDS refractory anemia with excess of blasts in trans-
formation (RAEB-t) and overt leukemia, multiple
myeloma partial remission (PR), NHL PR, non com-
plete remission (NCR), ATL PR. Conditioning regimens
were either conventional myeloablative conditioning
or reduced intensity conditioning (69 and 31%,
respectively). Prophylaxis of GVHD included cyclospo-
rin ± short term methotrexate (sMTX) for 30 cases and
FK506 + sMTX for 15 cases. Acute GVHD grade and
chronic GVHD grades were 0 (n = 12), 1 (n = 10), 2
(n = 16), 3 (n = 5), 4 (n = 2) and none (n = 17), lim-
ited type (n = 5), extensive type (n = 19) and not eval-
uate (n = 4), respectively.
Assay for human serum MIF by enzyme-linked
immunosorbent assay
MIF was measured in serum collected before and at
time points 1 month, 3 months, 6 months, and
1 year after allo-HSCT. We described this in detail in
our previous reports (Ohkawara et al., 2002). Serum
MIF concentrations were measured by enzyme-linked
immunosorbent assay (ELISA) specific for MIF. An
anti-human MIF IgG polyclonal antibody dissolved in
50 ll of phosphate-buffered saline (PBS) was added
to each well of a 96-well microtiter plate and left for
30 min at room temperature. After the plate had
been washed thrice with distilled water, all wells
were filled with PBS containing 0.5% bovine serum
albumin to block nonspecific blocking and left for
20 min at room temperature. After removal of the
blocking solution, serum samples were added in
duplicate to individual wells and incubated for 1 h at
room temperature. After the plate was washed thrice
with PBS containing 0.05% Tween-20 (washing buf-
fer), 50 ll of biotin-conjugated anti-MIF antibody
was added to each well. After incubation for 1 h at
Table 1. Clinical characteristics of patients




Median age (range) 37 (16–65)
Underlying diagnosis









Standard risk (AML 2nd CR, MDS RA,
CML 1 chronic phase (CP), NHL 1CR)
33
High risk (AML 3rd CR, NCR, MDS
RAEB-t and overt leukemia, MM PR,
NHL PR, NCR, CML blastic crisis (BC),
ATL PR)
11
Source of stem cells
Peripheral blood stem cell 4
Bone marrow 37
Cord blood 4
Human leukocyte antigen (HLA)
HLA-identical siblings 15
HLA-1 locus mismatch siblings 2
Matched-unrelated donors 22






Cyclosporin ± short term MTX 30













CML, chronic myelogenous leukemia; AML, acute mye-
logenous leukemia; MDS, myelodysplastic syndrome;
ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin
lymphoma; ATL, adult T-cell leukemia; MM, multiple
myeloma; AA, aplastic anemia; RA, refractory anemia;
PR, partial remission; CST, conventional stem cell trans-
plantation; RIST, reduced intensity stem cell transplanta-
tion; MTX, methotrexate; aGVHD, acute graft-versus-host
disease; cGVHD, chronic graft-versus-host disease.
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room temperature, the plate was again washed thrice
with washing buffer. Then avidin-conjugated anti-
human IgG antibody was added to each well, and
incubated 15 min at room temperature. After wash-
ing thrice with the washing buffer, the substrate
solution (50 ll) was added to each well. This sub-
strate solution (10 ml) contains 8 mg of o-phenylen-
ediamine and 4 ll of 30% H2O2 in citrate phosphate
buffer (pH 5.0). After incubation for 20 min at room
temperature, the reaction was terminated with 25 ll
of 4N sulfuric acid. The absorbance was measured at
492 nm by an ELISA plate reader (Model 3550; Bio-
rad, Hercules, CA, USA).
Statistical analysis
Differences between groups were analyzed by Stu-
dent’s t-test. Survival curves were plotted according to
the method of Kaplan and Meier, and comparison of
the curves was performed using the log-rank test.
RESULTS
We examined the association between pre-allo-HSCT
MIF levels and clinical characteristics. The mean
serum MIF levels were 10.0 ± 1.06 ng/ml. There was
no correlation between the pre-allo-HSCT MIF levels
Table 2. Serum MIF levels in patients along with the time course of HSCT by clinical characteristics
Variable
1 month 3 months 6 months
Number
Pre-MIF
levels (±SE) P-value Number
Pre-MIF
levels (±SE) P-value Number
Pre-MIF
levels (±SE) P-value
Mean 44 9.55 ± 0.95 – 38 9.54 ± 0.86 – 23 11.78 ± 1.73 –
Sex
Male 25 9.65 ± 1.38 0.91 22 9.98 ± 1.10 0.56 14 13.44 ± 2.59 0.24
Female 19 9.43 ± 1.29 16 8.94 ± 1.41 9 9.21 ± 1.71
Age (years)
<40 25 9.92 ± 1.23 0.67 23 8.66 ± 1.05 0.22 13 11.62 ± 2.36 0.92
3 40 19 9.07 ± 1.52 15 10.91 ± 1.46 10 11.99 ± 2.71
Risk
Standard risk 32 10.11 ± 1.22 0.23 30 9.66 ± 1.03 0.78 18 11.04 ± 1.67 0.59
High risk 11 7.90 ± 1.34 8 9.13 ± 1.52 5 14.44 ± 5.61
Source of stem cells
PBSC 4 7.63 ± 1.67 0.69 3 7.13 ± 2.53 0.63 2 15.30 ± 4.20 0.40
BM 36 10.06 ± 1.09 32 9.68 ± 0.98 19 12.03 ± 2.02
CB 4 6.95 ± 3.20 3 10.57 ± 2.65 2 5.90 ± 1.20
Conditioning regimen
CST 31 10.15 ± 1.26 0.24 28 10.15 ± 1.08 0.16 17 11.58 ± 2.08 0.85
RIST 13 8.13 ± 1.11 10 7.84 ± 1.19 6 12.35 ± 3.40
GVHD prophylaxis
CyA+ sMTX 30 9.48 ± 1.26 0.91 28 8.98 ± 0.95 0.33 18 11.76 ± 2.04 0.98
FK506 + sMTX 14 9.70 ± 1.35 10 11.14 ± 1.92 5 11.88 ± 3.61
aGVHD (overall grade)
Grade 0–1 21 9.05 ± 1.38 0.62 17 9.37 ± 1.34 0.86 8 11.30 ± 2.90 0.84
Grade 2–4 23 10.00 ± 1.33 21 9.69 ± 1.15 15 12.04 ± 2.24
cGVHD
None 17 10.01 ± 1.32 0.62 14 11.02 ± 1.48 0.59 7 9.78 ± 1.19 0.006
Limited type 5 11.02 ± 3.48 5 9.74 ± 3.45 2 2.35 ± 1.65
Extensive type 19 9.55 ± 1.71 17 8.43 ± 1.11 13 12.57 ± 2.18
MIF, macrophage migration inhibitory factor; HSCT, hematopoietic stem cell transplantation; PBSC, peripheral blood
stem cells; BM, bone marrow; CB, cord blood; CST, conventional stem cell transplantation; RIST, reduced intensity
stem cell transplantation; MTX, methotrexate; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-
host disease.
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and sex, age, risk, aGVHD, or cGVHD grades (data not
shown).
Table 2 shows serum MIF levels in patients along
the time course of allo-HSCT by clinical characteris-
tics. Mean values were 9.55 ± 1.06 ng/ml (n = 44) at
1 month, 9.54 ± 0.86 ng/ml (n = 38) at 3 months,
11.78 ± 1.73 ng/ml (n = 23) at 6 months and
8.06 ± 4.74 ng/ml (n = 12) at 1 year. We could not
find significant differences associating either sex, age,
risk, source of stem cells, conditioning regimen, GVHD
prophylaxis, or aGVHD grade with serum MIF levels.
However, patients who developed a GVHD displayed
significant increases in the peak serum MIF at onset
(14.46 ng ± 1.47 ng/ml) (n = 23, P = 0.009). Figure 1
shows the relationship between onset of aGVHD and
peak serum MIF in 23 patients in the aGVHD group.
We also examined the association between serum
MIF levels and cGVHD. Although we compared the
mean serum MIF levels among the three subgroups at
pretransplant and 6 months, we could not find signifi-
cance differences among these groups. However, we
did find significant differences in levels for patients
who developed extensive type cGVHD. Mean serum
MIF at 6 months (12.57 ± 2.18 ng/ml, n = 13) were sig-
nificantly higher than those before allo-HSCT (7.86 ±
1.17 ng/ml, n = 19, P = 0.04) (Figure 2). Therefore, we
speculated that serum MIF levels increase during the
active phase of both aGVHD and cGVHD.
Moreover, although we examined the association
between the serum MIF levels in patients and the sur-
vival rates, we could not find significance difference.
DISCUSSION
The present study demonstrated that serum MIF levels
after allo-HSCT was associated with aGVHD and an
extensive type of cGVHD. Strikingly, increased serum
















Figure 1. Comparison of before and after hematopoi-
etic stem cell transplantation serum macrophage
migration inhibitory factor levels in patients with
acute graft-versus-host disease (n = 23).
Figure 2. The change of serum
macrophage migration inhibi-
tory factor levels in chronic
graft-versus-host disease
(GVHD) patients. These results
are represented by solid and dot
line by symbols: none of chronic
GVHD ( ), limited type (¤),
extensive type ( ).
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had speculated, displayed a causal relationship
between MIF and aGVHD. However, we could not
find clear association between serum MIF levels after
allo-HSCT and survival rate.
Lo et al., (2002) reported that dramatic increase in
local MIF expression in aGVHD is associated with infil-
tration of activated T cells and macrophages in allo-
HSCT in humans. Moreover, they reported that serum
MIF levels of aGVHD patients at the onset of clinical
aGVHD were increased at least two to fourfolds, when
compared with those of allo-HSCT patients without aG-
VHD (Lo et al., 2002). Although we could not find a
clearly significant difference, serum MIF levels were
increased in the same patients before and after the
onset of aGVHD. So far, there have been no reports
that examined the association of serum MIF levels and
cGVHD. We have found for the first time that increased
serum MIF levels is associated with extensive type
cGVHD. These facts led to the speculation that MIF is
an important effector cytokine in aGVHD and cGVHD.
We examined the role of MIF in aGVHD after
HSCT using MIF KO mice as recipients in our previ-
ous study (Toubai et al., 2006). We found that MIF
had no significant effect on aGVHD in MIF KO recipi-
ent mice and serum MIF levels in MIF KO recipient
mice after allo-HSCT was not at all affected by the
development of a GVHD. However, significantly lower
a GVHD score were seen in the experiment using MIF
KO mice as the donors, when we compared the reci-
pient mice transplanted with BM and spleen cells (SP)
from MIF KO mice with those of the recipient mice
transplanted with BM and SP from WT-BALB/c mice.
These results indicated that MIF-deficient lymphocytes
did not induce severe aGVHD, suggesting a possible
abrogating effect of MIF on the development of aG-
VHD. However, we could not find any significant dif-
ferences between survival rates and serum MIF levels
associated with aGVHD in previous report. Although
we could not explain this finding, we speculated that
serum MIF levels may reflect outcomes of aGVHD and
cGVHD in humans very well.
Macrophage migration inhibitory factor stimulates
macrophage release of proinflammatory cytokines
such as TNF-a, interleukin 1b (IL-1b), IL-6, and IL-8
(Calandra et al., 1995; Donnelly et al., 1997). MIF is
known to be a potent angiogenic factor with pro-
inflammatory effects on the recruitment of human
peripheral blood monocytes via the up-regulation of
adhesion molecules [vascular cell adhesion molecule-
1 (VCAM-1) and intercellular adhesion molecule-1
(ICAM-1)] (Asif Amin et al., 2006). Therefore, MIF
and its signaling pathways may be potential targets in
MN-dependent inflammatory diseases such as RA and
atherosclerosis (Asif Amin et al., 2006).
Macrophage migration inhibitory factor plays a
vital role in the effector stage of autoimmune injury
initiated by type 1 helper (Th1) cells (Bernhagen et al.,
1996; Lan et al., 1997; Selvi et al., 2003). aGVHD is
similarly dependent on donor-specific cytokine-secret-
ing T cells (Ferrara, Cooke & Teshima, 2003). Serum
MIF levels at the onset of aGVHD were increased at
least twofold compared with the levels before allo-
HSCT. It has been reported that intrinsic skin and
colon cells are the major sites of MIF production in
aGVHD. These findings suggest that MIF might play a
role in aGVHD.
Our study results have important therapeutic
implications. The observation that MIF is increased in
association with aGVHD and cGVHD suggests that its
inactivation may be explored as a target of anti-GVHD
therapy. Functional studies using anti-MIF antibody
in an experimental model of aGVHD may be helpful
in defining its role in the treatment of aGVHD.
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